Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hedyotis diffusa is a small flowering herb native to East Asia and widely used in Traditional Chinese Medicine (TCM), where it is known as Bai Hua She She Cao (白花蛇舌草). Traditionally employed for its detoxifying and anti-inflammatory properties, it has been used to treat infections, abscesses, inflammations, and various cancers. Modern research highlights its pharmacological activities including anticancer effects—particularly against digestive system cancers (such as colon and liver cancer), lung cancer, and cervical cancer—by inducing apoptosis in tumor cells and inhibiting metastasis. The plant contains bioactive compounds such as flavonoids, polysaccharides, and terpenoids that contribute to its anti-inflammatory, antioxidant, immunomodulatory, antimicrobial activities. Hedyotis diffusa is typically administered orally in the form of decoctions or extracts[1][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hedyotis diffusa.